HRP20210113T1 - Stabilizirani topljivi prefuzijski rsv f protein za upotrebu u profilaksi rsv infekcije - Google Patents

Stabilizirani topljivi prefuzijski rsv f protein za upotrebu u profilaksi rsv infekcije Download PDF

Info

Publication number
HRP20210113T1
HRP20210113T1 HRP20210113TT HRP20210113T HRP20210113T1 HR P20210113 T1 HRP20210113 T1 HR P20210113T1 HR P20210113T T HRP20210113T T HR P20210113TT HR P20210113 T HRP20210113 T HR P20210113T HR P20210113 T1 HRP20210113 T1 HR P20210113T1
Authority
HR
Croatia
Prior art keywords
seq
protein
rsv
region
prefusion
Prior art date
Application number
HRP20210113TT
Other languages
English (en)
Inventor
Anders KRARUP
Johannes Petrus Maria Langedijk
Original Assignee
Janssen Vaccines & Prevention B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention B.V. filed Critical Janssen Vaccines & Prevention B.V.
Publication of HRP20210113T1 publication Critical patent/HRP20210113T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)

Claims (3)

1. Rekombinantni prefuzijski (F) protein respiratornog sincicijskog virusa (RSV), koji sadrži aminokiselinsku sekvencu SEQ ID NO: 1 naznačen time što je za upotrebu u profilaksi RSV infekcije.
2. Prefuzijski RSV F protein; za upotrebu prema patentnom zahtjevu 1, naznačen time što sadrži barem jedan epitop koji je specifičan za prefuzijski konformacijski F protein, pri čemu je najmanje jedan epitop prepoznat po prefuzijskom specifičnom monoklonskom protutijelu, koje sadrži CDR1 regiju teškog lanca od SEQ ID NO: 4, CDR2 regiju teškog lanca od SEQ ID NO: 5, CDR3 regiju teškog lanca od SEQ ID NO: 6 i CDR1 regiju lakog lanca od SEQ ID NO: 7, CDR2 regiju lakog lanca od SEQ ID NO: 8, i CDR3 regiju lakog lanca od SEQ ID NO: 9 i/ili prefuzijskom specifičnom monoklonskom protutijelu, koje sadrži CDR1 regiju teškog lanca od SEQ ID NO: 10, CDR2 regiju teškog lanca od SEQ ID NO: 11, CDR3 regiju teškog lanca od SEQ ID NO: 12 i CDR1 regiju lakog lanca od SEQ ID NO: 13, CDR2 regiju lakog lanca od SEQ ID NO: 14, te CDR3 regiju lakog lanca od SEQ ID NO: 15.
3. Prefuzijski RSV F protein za upotrebu prema patentnom zahtjevu 1 ili 2, naznačen time što je protein trimerni.
HRP20210113TT 2016-04-05 2021-01-22 Stabilizirani topljivi prefuzijski rsv f protein za upotrebu u profilaksi rsv infekcije HRP20210113T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163810 2016-04-05
EP17715692.4A EP3439672B1 (en) 2016-04-05 2017-04-04 Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
PCT/EP2017/057962 WO2017174568A1 (en) 2016-04-05 2017-04-04 Stabilized soluble pre-fusion rsv f proteins

Publications (1)

Publication Number Publication Date
HRP20210113T1 true HRP20210113T1 (hr) 2021-03-05

Family

ID=55752165

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210113TT HRP20210113T1 (hr) 2016-04-05 2021-01-22 Stabilizirani topljivi prefuzijski rsv f protein za upotrebu u profilaksi rsv infekcije

Country Status (29)

Country Link
US (2) US11155583B2 (hr)
EP (2) EP3439672B1 (hr)
JP (2) JP7088841B2 (hr)
KR (2) KR102506895B1 (hr)
CN (2) CN109069616A (hr)
AU (2) AU2017248021B2 (hr)
BR (1) BR112018070013A2 (hr)
CA (1) CA3018941A1 (hr)
CL (1) CL2018002826A1 (hr)
CY (1) CY1124019T1 (hr)
DK (1) DK3439672T3 (hr)
EA (2) EA039095B1 (hr)
ES (1) ES2858315T3 (hr)
HR (1) HRP20210113T1 (hr)
HU (1) HUE053027T2 (hr)
IL (2) IL262108B2 (hr)
LT (1) LT3439672T (hr)
MA (2) MA52910A (hr)
MD (1) MD3439672T2 (hr)
MX (2) MX2018012094A (hr)
MY (1) MY190320A (hr)
PE (1) PE20190420A1 (hr)
PH (1) PH12018501962A1 (hr)
PL (1) PL3439672T3 (hr)
PT (1) PT3439672T (hr)
RS (1) RS61456B1 (hr)
SG (1) SG11201807913XA (hr)
SI (1) SI3439672T1 (hr)
WO (1) WO2017174568A1 (hr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA039803B1 (ru) * 2013-04-25 2022-03-15 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv до слияния
ES2773309T3 (es) 2013-07-25 2020-07-10 Calder Biosciences Inc Proteínas F de pre-fusión de VRS estabilizadas conformacionalmente
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
JP7088841B2 (ja) * 2016-04-05 2022-06-21 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された可溶性融合前ｒｓｖ ｆタンパク質
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
EP3464331B1 (en) 2016-05-30 2020-10-28 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
RU2019130167A (ru) 2017-04-04 2021-05-05 Юниверсити Оф Вашингтон Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение
US11771755B2 (en) 2018-02-28 2023-10-03 University Of Washington Self-asssembling nanostructure vaccines
JP2022513025A (ja) 2018-11-13 2022-02-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆタンパク質
CA3177062A1 (en) 2020-04-02 2021-10-07 Janssen Vaccines & Prevention B.V. Stabilized vaccine compositions
CN116096406A (zh) 2020-06-29 2023-05-09 扬森疫苗与预防公司 针对呼吸道合胞病毒感染的疫苗组合
JP2024509756A (ja) 2021-02-19 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆｂ抗原
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
DE69535178T2 (de) 1994-06-10 2006-12-14 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
JP4051416B2 (ja) 1995-06-15 2008-02-27 クルーセル ホランド ベスローテン フェンノートシャップ 遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
ATE550429T1 (de) 1996-11-20 2012-04-15 Crucell Holland Bv Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
JP2000509614A (ja) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド アデノウイルスｅ１−相補性細胞系
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
KR100912362B1 (ko) 1998-02-17 2009-08-19 쉐링 코포레이션 바이러스 제제의 정제방법
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
EP1977764A1 (en) 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
WO2000070071A1 (en) 1999-05-17 2000-11-23 Crucell Holland B.V. Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
CA2415688A1 (en) 2000-05-08 2001-11-15 Anand Rao Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
PL371261A1 (en) 2002-01-18 2005-06-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
NZ534865A (en) 2002-04-25 2008-07-31 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
US20050196854A1 (en) 2002-05-14 2005-09-08 Konz John O.Jr. Methods of adenovirus purification
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2003268210A1 (en) 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
US8772256B2 (en) 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
SI2222710T1 (sl) 2007-12-24 2016-11-30 Id Biomedical Corporation Of Quebec Rekombinatni RSV antigeni
MX2011004292A (es) 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.
ES2898235T3 (es) 2009-02-02 2022-03-04 Glaxosmithkline Biologicals Sa Secuencias de aminoácidos y de ácidos nucleicos de adenovirus de simio, vectores que las contienen, y sus usos
CA2766211A1 (en) 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
WO2010149743A2 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine
EP3988115A3 (en) 2009-07-15 2022-08-17 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
EA023179B1 (ru) 2009-08-13 2016-05-31 Круселл Холланд Б.В. Антитела против респираторного синцитиального вируса (pcb) и способы их применения
AU2010305765B2 (en) 2009-10-15 2015-07-02 Crucell Holland B.V. Method for the purification of adenovirus particles
CN102575233B (zh) 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 从高细胞密度培养物纯化腺病毒的方法
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
EA023816B1 (ru) 2010-02-15 2016-07-29 Круселл Холланд Б.В. СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26
KR101896124B1 (ko) 2010-07-09 2018-09-07 얀센 백신스 앤드 프리벤션 비.브이. 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법
LT2707385T (lt) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Iš anksto sulieti rsv f antigenai
AU2013231423B2 (en) 2012-03-12 2018-10-04 Janssen Vaccines & Prevention B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CN104334188B (zh) 2012-03-22 2016-08-24 克鲁塞尔荷兰公司 抗rsv疫苗
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CN112851766A (zh) 2013-03-13 2021-05-28 美国政府(由卫生和人类服务部的部长所代表) 融合前rsv f蛋白和其用途
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
CA2906960C (en) * 2013-03-15 2021-07-20 Xiamen University Epitope of rsv fusion protein and antibody recognizing the epitope
CA2908878C (en) 2013-04-15 2021-06-29 Crucell Holland B.V. Human antibodies binding to rsv g protein
CA2908921C (en) 2013-04-15 2022-07-19 Crucell Holland B.V. Human antibodies binding to rsv g protein
EA039803B1 (ru) * 2013-04-25 2022-03-15 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv до слияния
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
ES2773309T3 (es) 2013-07-25 2020-07-10 Calder Biosciences Inc Proteínas F de pre-fusión de VRS estabilizadas conformacionalmente
CA2923352C (en) 2013-09-19 2022-05-03 Crucell Holland B.V. Stable adenovirus formulations
JP7088841B2 (ja) * 2016-04-05 2022-06-21 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された可溶性融合前ｒｓｖ ｆタンパク質
EA201892250A1 (ru) * 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv

Also Published As

Publication number Publication date
KR20220041966A (ko) 2022-04-01
AU2017248021A1 (en) 2018-10-04
WO2017174568A1 (en) 2017-10-12
JP7088841B2 (ja) 2022-06-21
MA52910A (fr) 2021-04-21
LT3439672T (lt) 2021-01-25
MX2022015257A (es) 2023-01-11
ES2858315T3 (es) 2021-09-30
KR20180131584A (ko) 2018-12-10
IL262108B (en) 2022-12-01
MA43763B1 (fr) 2021-03-31
IL262108A (en) 2018-11-29
IL291604A (en) 2022-05-01
CN116063551A (zh) 2023-05-05
SI3439672T1 (sl) 2021-02-26
EA039095B1 (ru) 2021-12-03
AU2021209185B2 (en) 2023-06-01
CL2018002826A1 (es) 2018-11-16
PE20190420A1 (es) 2019-03-19
CN109069616A (zh) 2018-12-21
AU2021209185A1 (en) 2021-08-19
HUE053027T2 (hu) 2021-06-28
EP3439672B1 (en) 2020-11-25
IL291604B1 (en) 2023-10-01
SG11201807913XA (en) 2018-10-30
EA201892251A1 (ru) 2019-03-29
IL291604B2 (en) 2024-02-01
RS61456B1 (sr) 2021-03-31
CY1124019T1 (el) 2022-05-27
JP2022101561A (ja) 2022-07-06
AU2017248021B2 (en) 2021-08-12
PL3439672T3 (pl) 2021-06-14
MD3439672T2 (ro) 2021-04-30
US11155583B2 (en) 2021-10-26
MA43763A (fr) 2019-02-13
MY190320A (en) 2022-04-13
PT3439672T (pt) 2021-02-24
KR102506895B1 (ko) 2023-03-08
JP7362819B2 (ja) 2023-10-17
EA202191622A1 (ru) 2022-01-31
BR112018070013A2 (pt) 2019-02-05
JP2019513377A (ja) 2019-05-30
MX2018012094A (es) 2019-01-10
EP3439672A1 (en) 2019-02-13
US20190119330A1 (en) 2019-04-25
IL262108B2 (en) 2023-04-01
DK3439672T3 (da) 2021-02-15
CA3018941A1 (en) 2017-10-12
US20220089652A1 (en) 2022-03-24
EP3808374A1 (en) 2021-04-21
PH12018501962A1 (en) 2019-06-24

Similar Documents

Publication Publication Date Title
HRP20210113T1 (hr) Stabilizirani topljivi prefuzijski rsv f protein za upotrebu u profilaksi rsv infekcije
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
HRP20191299T1 (hr) Formulacije protutijela
HRP20200607T1 (hr) Rsv-specifična protutijela i njihovi funkcionalni dijelovi
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
HRP20191608T1 (hr) Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida
HRP20190714T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
PE20210377A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
HRP20230844T1 (hr) Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe
HRP20221262T1 (hr) Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
HRP20211935T1 (hr) Protutijela anti-alfa-sinuklein i njihove uporabe
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
NZ715896A (en) Humanized or chimeric cd3 antibodies
HRP20200404T1 (hr) Epitopi proteina f respiratornog sincijalnog virusa
RU2016100892A (ru) Антитела против tweakr и их применение
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
HRP20210604T1 (hr) Humanizirano anti-hmgb1 antitijelo ili njegov fragment koji veže antigen
WO2014144542A3 (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
HRP20201811T1 (hr) Protutijela koja snažno neutraliziraju virus bjesnoće i druge lyssaviruse i njihova upotreba